Scientists, advocates voice objections to von Eschenbach’s conflicts, 2015.
Cancer Leadership Council letter calls for permanent leadership of NCI and FDA.
Cancer center directors to develop blueprint for progress that’s “honest,” M.D. Anderson’s John Mendelsohn says.
Also Von Eschenbach role in industry program raises new concerns of conflict of interest.
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- Cancer vaccine policy in limbo as CDC keeps canceling advisory meetings









